Clinical Trials Browser

Phase 2 × Not yet recruiting × Plasma cell × Clear all

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07224672 2026-03-17

ALANIS

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07382739 2026-02-17

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07409454 2026-02-13

CAREMM-007

Phase 2 Not yet recruiting

Multiple Myeloma

NCT05874193 2026-02-05

COSTA

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07009899 2026-01-29

RECLAIM

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07348393 2026-01-16

Mezi-KD

Phase 2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis

NCT07292272 2025-12-26

Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07227311 2025-11-12

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07085728 2025-08-22

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07107529 2025-08-12

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07070934 2025-07-17

ASCTvsCAR-T

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07055724 2025-07-09

Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis

NCT06963866 2025-05-09

ASCTvsCAR-T

Phase 2 Not yet recruiting

Multiple Myeloma

NCT06931704 2025-04-23

IFM 2024_06

Phase 2 Not yet recruiting

Multiple Myeloma

NCT06880601 2025-04-03

TALIM

Phase 2 Not yet recruiting

Multiple Myeloma, Recurrence

NCT06744894 2024-12-20

SIL as Maintenance Therapy in Multiple Myeloma

Phase 2 Not yet recruiting

Multiple Myeloma

NCT05909826 2023-06-18

KMM-KCd

Phase 2 Not yet recruiting

Multiple Myeloma

NCT05527340 2022-09-02

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Phase 2 Not yet recruiting

Multiple Myeloma